By Dr. Dina Seif, MD | OC Ketamine Therapy | May 2026
Fibromyalgia is one of the most isolating diagnoses in medicine. Not because it isn’t real — it’s profoundly real, and the pain is profoundly real — but because the path to diagnosis is so long, the treatment options so limited, and the dismissiveness from some providers so consistent that many fibromyalgia patients arrive at my door having been told, in one way or another, that it’s all in their head.
It isn’t. And the neuroscience of why fibromyalgia causes the suffering it does actually explains why ketamine — a treatment most people associate with depression — may be one of the most promising therapeutic options for fibromyalgia patients who haven’t found adequate relief.
I want to walk through the biology, the evidence, and the honest limitations, because fibromyalgia patients deserve practitioners who speak to them directly and don’t sugarcoat the complexity of their condition.
The Central Sensitization Connection
Fibromyalgia is fundamentally a disorder of central sensitization — a state in which the central nervous system has become pathologically amplified in its processing of pain signals. Think of it as a gain dial on your pain system that’s been turned up too high. Stimuli that shouldn’t be painful become painful. Existing pain becomes amplified beyond what the peripheral injury (if any) would predict.
The neurotransmitter most central to this process is glutamate, and specifically the NMDA glutamate receptor. Research consistently shows that fibromyalgia patients have elevated glutamate levels in pain-processing regions of the brain and spinal cord, and that NMDA receptor hyperactivity is a key driver of central sensitization (Taylor et al., 2021).
Ketamine is an NMDA receptor antagonist. That means it directly blocks the receptor that’s driving the central sensitization in fibromyalgia. This is not a coincidence or a secondary mechanism. It’s the same receptor, in the same circuits, that’s producing the pathological pain amplification. From a pharmacological standpoint, ketamine for fibromyalgia is one of the more directly relevant treatments we have for this mechanism.
What I notice clinically — and this is something I pay close attention to — is that fibromyalgia patients often describe their infusion experience differently than depression patients. The relief tends to be more somatic, more bodily. Several patients have described it as a “decompression” or a loosening of something tight they hadn’t consciously noticed was tight. That sensory shift is consistent with what you’d expect from central sensitization downregulation.
Another approach that targets this same system from a different angle is stellate ganglion block (SGB), which we’ve recently introduced in our practice. SGB works by modulating the sympathetic nervous system — essentially interrupting a chronic “fight-or-flight” signal that can amplify both pain and stress responses. For some patients, particularly those with significant autonomic dysregulation or trauma-related symptoms, stellate ganglion block in Newport Beach can be used on its own or in conjunction with ketamine to help reduce that baseline state of overactivation.
What the Research Shows
The evidence base for ketamine in fibromyalgia is smaller than for depression or CRPS, but it’s meaningful. Taylor et al. (2021) provided a comprehensive review of the pharmacological mechanisms supporting NMDA antagonist use in central sensitization syndromes, including fibromyalgia. Multiple smaller trials have demonstrated that IV ketamine produces significant, clinically meaningful pain reduction in fibromyalgia patients, with effects persisting well beyond the infusion window — likely reflecting not just acute receptor blockade, but downstream anti-inflammatory and neuroplastic changes (Fava et al., 2020).
For fibromyalgia patients who also carry co-occurring depression or anxiety — which describes a substantial majority of fibromyalgia patients in clinical populations — the overlap is even more clinically compelling. Ketamine addresses the mood component and the pain component through the same pharmacological mechanism. That’s a genuinely unusual therapeutic profile. Most pain medications don’t do much for mood, and most psychiatric medications don’t do much for central sensitization. Ketamine sits at the intersection. To understand how this mechanism translates to pain conditions broadly, our post on unlocking relief through ketamine for chronic pain explores the evidence in depth.
Can ketamine cure fibromyalgia? No. I won’t tell you that. The chronicity and complexity of fibromyalgia means that a course of ketamine infusions is not a one-and-done solution. In practice, these treatments are often most effective when they’re part of a broader strategy — addressing not just the pain signal itself, but the nervous system patterns that sustain it. For patients who’ve cycled through opiates, Lyrica, Cymbalta, gabapentin, muscle relaxants, nerve stimulators, pain pumps, and physical therapy protocols without adequate relief, ketamine represents a mechanistically distinct and genuinely promising option.
Honest Considerations
Not everyone with fibromyalgia is a candidate for ketamine. Patients with uncontrolled hypertension, active psychosis, certain cardiac conditions, or a history of substance use disorder require careful evaluation before proceeding. Cost and insurance coverage are real barriers — ketamine for pain management is not covered by most commercial insurance, and I won’t pretend otherwise.
What I can offer is a thorough consultation, a personalized assessment, and a genuine commitment to giving you the most honest picture of whether ketamine is likely to help in your specific situation. If it’s not the right fit, I’ll tell you that too — and help you think through what is.
If you’re living with fibromyalgia pain that hasn’t responded to standard treatments, you deserve to know about every evidence-based option available to you. Contact us to schedule a consultation and start the conversation.
References
1. Taylor SS et al. (2021). Complex Regional Pain Syndrome: A Comprehensive Review. Pain and Therapy. https://doi.org/10.1007/s40122-021-00279-4
2. Fava M et al. (2020). Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD). Molecular Psychiatry. https://doi.org/10.1038/s41380-018-0256-5
3. Yavi M et al. (2022). Ketamine treatment for depression: a review. Discover Mental Health. https://doi.org/10.1007/s44192-022-00012-3
About Dr. Dina Seif
Dina Seif, MD, believes that with the right mindset and support, every one of us has the potential to transform and heal our minds. She specializes in creating a personalized plan for each patient and is committed to providing a supportive healing environment for your journey. Dr. Seif is a member of the American Society of Ketamine Physicians and was recognized as a Physician of Excellence by the Orange County Medical Association. Dr. Seif has 15+ years of experience with ketamine in the emergency setting and founded one of the first ketamine practices in Orange County in 2019. She has administered thousands of infusions and cared for hundreds of patients from around the world. Dr. Seif is board-certified in Emergency Medicine and is a graduate of the University of California, Irvine, where she attended college, medical school, and business school. After an internship in Internal Medicine at St. Vincent’s Medical Center in New York, she returned to California for Emergency Medicine residency at LAC+USC Medical Center where she also completed a fellowship in Emergency Ultrasound and was a Professor of Clinical Emergency Medicine at Keck School of Medicine of USC for 5 years.
Medical Disclaimer
This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. If you are experiencing a mental health crisis or having thoughts of self-harm, please call or text 988 (Suicide and Crisis Lifeline) or go to your nearest emergency room immediately. Always consult with a qualified healthcare provider before starting any new treatment or making changes to your existing treatment plan. Individual results may vary, and no outcomes are guaranteed.